The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Spatial regulation of receptor tyrosine kinases in development and cancer
Open accessAbstract
During development and tissue homeostasis, patterns of cellular organization, proliferation and movement are highly choreographed. Receptor tyrosine kinases (RTKs) have a crucial role in establishing these patterns. Individual cells and tissues exhibit tight spatial control of the RTKs that they express, enabling tissue morphogenesis and function, while preventing unwarranted cell division and migration that can contribute to tumorigenesis. Indeed, RTKs are deregulated in most human cancers and are a major focus of targeted therapeutics. A growing appreciation of the essential role of spatial RTK regulation during development prompts the realization that spatial deregulation of RTKs is likely to contribute broadly to cancer development and may affect the sensitivity and resistance of cancer to pharmacological RTK inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Dynamin 2 mediates PDGFRα-SHP-2-promoted glioblastoma growth and invasion
Feng, H., Liu, K. W., Guo, P., Zhang, P., Cheng, T., McNiven, M. A., Johnson, G. R., Hu, B., & Cheng, S. (2011) · Oncogene · doi:10.1038/onc.2011.436 · Cited by 73
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc822 · Cited by 6,628
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia
Gerhardt, H., Golding, M., Fruttiger, M., Ruhrberg, C., Lundkvist, A., Abramsson, A., Jeltsch, M., Mitchell, C., Alitalo, K., Shima, D., et al. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200302047 · Cited by 2,894
Collective cell migration in morphogenesis, regeneration and cancer
Friedl, P., & Gilmour, D. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2720 · Cited by 2,712
Tumor heterogeneity: Causes and consequences
Marusyk, A., & Polyak, K. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.11.002 · Cited by 1,602
Cited by
Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms
Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C., & Flavell, R. A. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3611 · Cited by 2,000
Mechanisms of receptor tyrosine kinase activation in cancer
Du, Z., & Lovly, C. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0782-4 · Cited by 1,066
Therapy for Fibrotic Diseases: Nearing the Starting Line
Friedman, S. L., Sheppard, D., Duffield, J. S., & Violette, S. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004700 · Cited by 655
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
Butler, L. M., Perone, Y., Dehairs, J., Lupien, L. E., de Laat, V., Talebi, A., Loda, M., Kinlaw, W. B., & Swinnen, J. V. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.013 · Cited by 589
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M.-C. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 445
EGFR signaling pathway as therapeutic target in human cancers
Levantini, E., Maroni, G., Del Re, M., & Tenen, D. G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.002 · Cited by 356
Role of nonresolving inflammation in hepatocellular carcinoma development and progression
Yu, L.-X., Ling, Y., & Wang, H.-Y. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0048-z · Cited by 301
Negri, A., Naponelli, V., Rizzi, F., & Bettuzzi, S. (2018) · Nutrients · doi:10.3390/nu10121936 · Cited by 269
Spatial control of membrane receptor function using ligand nanocalipers
Shaw, A., Lundin, V., Petrova, E., Fördős, F., Benson, E., Al-Amin, A., Herland, A., Blokzijl, A., Högberg, B., & Teixeira, A. I. (2014) · Nature Methods · doi:10.1038/nmeth.3025 · Cited by 264
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
GOLM1 modulates EGFR/RTK cell-surface recycling to drive hepatocellular carcinoma metastasis
Ye, Q.-H., Zhu, W.-W., Zhang, J.-B., Qin, Y., Lu, M., Lin, G.-L., Guo, L., Zhang, B., Lin, Z.-H., Roessler, S., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.07.017 · Cited by 228
“Derailed endocytosis and recycling of cell-surface proteins, including RTKs, are regarded as a multifaceted hallmark of malignant cells (Mosesson et al., 2008; Parachoniak and Park, 2012; Casaletto and McClatchey, 2012).”
BackgroundHota, P. K., & Buck, M. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1019-0 · Cited by 170
Müller, M., Gräbnitz, F., Barandun, N., Shen, Y., Wendt, F., Steiner, S. N., Severin, Y., Vetterli, S. U., Mondal, M., Prudent, J. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27280-x · Cited by 101
Takeda, T., Tsubaki, M., Matsuda, T., Kimura, A., Jinushi, M., Obana, T., Takegami, M., & Nishida, S. (2022) · Oncology Reports · doi:10.3892/or.2022.8320 · Cited by 17
Metadata
- Authors
- Casaletto, J. B., & McClatchey, A. I.
- Venue
- Nature Reviews Cancer
- Published
- 2012-05-24
- Volume
- 12
- Issue
- 6
- Pages
- 387-400
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2085365699
- Cited by
- 359
- References
- 149
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.